The Alinity ci-series instruments for clinical chemistry and immunoassay diagnostics from Abbott, Abbott Park, Ill, have obtained the CE mark and are now available in Europe and other countries that recognize the CE mark. The testing systems help labs run more tests in less time, reduce human error, and increase testing productivity.
“Better healthcare begins with a high-performing lab,” says Brian Blaser, executive vice president of diagnostics products at Abbott. “Abbott’s Alinity family is an unprecedented approach to providing a more efficient, complete lab solution that no competitor in the industry can match. Abbott is bringing meaningful innovation to diagnostic testing, elevating the role it plays in improving clinical decisionmaking and delivering high quality care to patients.”
Offering a flexible, modular design, the Alinity c clinical chemistry system and the Alinity i immunoassay system can operate individually or as an integrated Alinity ci-series unit, all within half the size of current diagnostics systems.
In addition to greater capacity in a smaller footprint, the Alinity ci-series has a number of new features based on customer insights. Features include increased loading capacity for samples and tests; separate lanes to run urgent tests without interrupting lab workflow; continuous access for reloading solutions and supplies without prolonged pausing of testing cycles; solution bottles keyed to ensure insertion only in the correct location; and an intuitive menu design and user-friendly interface, common to the Alinity family of instruments, for simpler training of lab technicians.
“To design the Alinity ci systems, we spent countless hours with our customers in the design phase to ensure that we built a solution for the issues they face every day, including higher testing volumes; a lack of staffing and space; and complex, time-intensive processes and instruments,” says Dennis Gilbert, PhD, vice president of research and development in the diagnostics division at Abbott. “The Alinity family of systems simplifies diagnostic testing while delivering results that drive better patient outcomes.”
Abbott will launch clinical chemistry and immunoassay tests for the Alinity ci-series in phases, with a complete menu of tests available within a year of launch, according to the company. Clinical chemistry tests detect the presence of different chemicals in the blood and include tests such as calcium, glucose, potassium, and sodium. Immunoassay methods use antibody or antigen recognition to detect complex molecules and provide information related to cancer, cardiac risk factors, hormone levels, infectious diseases, therapeutic drugs, and thyroid issues.
The Alinity portfolio includes systems for blood and plasma screening, clinical chemistry, hematology, immunoassays, molecular diagnostics, and point-of-care testing, along with Abbott’s AlinIQ—a first-of-its-kind, holistic suite of professional services that combines expertise with process analysis and informatics.
For more information, visit Abbott.